Home / Business & Investment News / Braincure-Biotech.com Engages Mary Tien-tsan, Industry Veteran, as Research Vice President

Braincure-Biotech.com Engages Mary Tien-tsan, Industry Veteran, as Research Vice President

Related eBooks

Braincure-Biotech.com Engages Mary Tien-tsan, Industry Veteran, as Research Vice President

The appointment comes as Braincure readies itself for clinical trials in Asia for the evaluation of a new approach to Alzheimers treatment

Online PR News – 06-November-2015 – Braincure-Biotech.com today announced that the company has engaged biotech industry veteran Mary Tien-tsan to serve on the executive team, as Research and Technology vice president, reporting to CEO Suhon Horng. Tien-tsan will work cross-functionally, driving business development, and growth strategies communication and investor relations. She will also serve as a Research and Technology spokesperson.

We are really excited that Mary is joining our executive team, said Mr. Horng. With more than two decades of experience in healthcare, and a focus on biotechnology and the life sciences, Mary has the expertise to work with teams across the company during this critical juncture.

Tien-tsan, a 20-year veteran of the healthcare industry, has worked with more than 100 life sciences, pharmaceutical and medical device and diagnostic companies across multiple disciplines. She has a particular focus on strategic planning and growth strategies for young companies and identifying opportunities to leverage success in visible ways as goals are met. Tien-tsan holds an undergraduate degree in medicine and a MBA in finance. She is a member of multiple industry organizations, and an invited speaker, author and blogger.

Braincure Biotech is preparing to evaluate an approach to Alzheimers treatment that has never before been studied in a clinically significant way, using an innovative device, said Tien-tsan. The driving vision behind our effort is to offer a potential new treatment in the Alzheimers space that has significant impact on disease progression. The opportunity to join the company at this time and help make this happen represents a professional challenge that I fully embrace.

About Braincure Biotech – http://www.braincure-biotech.com/
Braincure-Biotech.com is a state-of-the-art technology research company that uses discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimers disease, other forms of dementia, and mechanistically similar disorders. Braincure Biotechs strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. The goal of the firm is to discover and develop novel, disease modifying therapies for dementia and mechanistically similar disorders. The highly professional and acclaimed team of scientists maintains an innovative and motivating environment in which every employee has the possibility to contribute to our joint success and to grow individually.

Company Contact Information

Check Also

Consider Kirkland Lake Gold (KL), A Gold Mining Growth Stock

This week we are looking at another of the Investor’s Business Daily (IBD) Top 50 List companies.  We use this list in one of our options portfolios to spot outperforming stocks and place option spreads that take advantage of the momentum. Last week was a great one for the market (SPY up 2.6%) and an even better one for the Terry’s Tips 8 actual option portfolios.  Every one made gains, and the composite average picked up 11%, a record we are quite proud of.  Terry Consider Kirkland Lake Gold (KL), A Gold Mining Growth Stock The Investor’s Business Daily recently posted an article which started out by stating “Gold might not come to mind first when you think of growth stocks” which is very true.  Take a look at this article for the full write up and the reasoning behind why they see growth potential in this stock.  Also check out Kirkland Lake Gold Receives Consensus Rating of “Buy” from Analysts.

Leave a Reply

Your email address will not be published. Required fields are marked *